Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
India
· Delayed Price · Currency is INR | Market Cap | 13.80B |
| Revenue (ttm) | 2.99B |
| Net Income (ttm) | 430.82M |
| Shares Out | 67.14M |
| EPS (ttm) | 6.31 |
| PE Ratio | 32.58 |
| Forward PE | n/a |
| Dividend | 2.50 (1.23%) |
| Ex-Dividend Date | Sep 12, 2025 |
| Volume | 232,395 |
| Average Volume | 207,449 |
| Open | 206.70 |
| Previous Close | 205.55 |
| Day's Range | 205.20 - 212.80 |
| 52-Week Range | 155.00 - 301.65 |
| Beta | -0.47 |
| RSI | 68.42 |
| Earnings Date | Apr 27, 2026 |
About Jagsonpal Pharmaceuticals
Jagsonpal Pharmaceuticals Limited engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally. It offers pharmaceutical formulations and products in the areas of gynaecology, orthopaedics, dermatology, and paediatrics. The company provides drugs in the form of tablets, softgels, injections, capsules, and syrups. Jagsonpal Pharmaceuticals Limited was incorporated in 1978 and is based in Gurugram, India. [Read more]
Financial Performance
In fiscal year 2026, Jagsonpal Pharmaceuticals's revenue was 2.99 billion, an increase of 11.35% compared to the previous year's 2.69 billion. Earnings were 430.82 million, a decrease of -22.18%.
Financial StatementsNews
Jagsonpal Pharmaceuticals Transcript: Q4 25/26
Q4 saw a strong recovery with 10% revenue growth and 31% PAT growth, outperforming the pharma market. The company maintains guidance to grow at 1.5x industry rates, with robust cash returns to shareholders and continued focus on core therapies and productivity.
Jagsonpal Pharmaceuticals Ltd (BOM:507789) Q3 2026 Earnings Call Highlights: Strategic Growth ...
Jagsonpal Pharmaceuticals Ltd (BOM:507789) Q3 2026 Earnings Call Highlights: Strategic Growth Amidst Market Challenges
Q3 2026 Jagsonpal Pharmaceuticals Ltd Earnings Call Transcript
Q3 2026 Jagsonpal Pharmaceuticals Ltd Earnings Call Transcript
Jagsonpal Pharmaceuticals Transcript: Q3 25/26
Q3 was flat with revenue at INR 73 crores and 10% PAT growth, while the nine-month period saw 6% revenue and 12.5% PAT growth. Strategic realignment and SKU rationalization impacted short-term results, but double-digit growth is expected from Q4, supported by strong cash generation and a focus on high-potential brands.
Q2 2026 Jagsonpal Pharmaceuticals Ltd Earnings Call Transcript
Q2 2026 Jagsonpal Pharmaceuticals Ltd Earnings Call Transcript
Jagsonpal Pharmaceuticals Transcript: Q2 25/26
Revenue grew 10% year-over-year in H1 FY26, with PAT up 39% and strong cash reserves maintained despite a higher dividend payout. Management expects low double-digit growth for FY26 and ongoing improvements in MR productivity and brand performance.
Jagsonpal Pharmaceuticals shares decline nearly 3% today as revenue and EBITDA soften in Q2
Shares of Jagsonpal Pharmaceuticals traded lower on Tuesday, November 4, falling 2.86% to Rs 220 in morning trade, after the...
Jagsonpal Pharmaceuticals Transcript: Q1 25/26
Q1 FY26 saw 23% revenue growth, margin expansion, and doubled PAT, driven by strong brands and Yash Pharma integration. Guidance for 15% annual growth and 100-150 bps margin expansion is maintained, with robust cash reserves and a disciplined acquisition strategy.
Jagsonpal Pharmaceuticals Transcript: Q4 24/25
FY 2025 saw 29% revenue and 59% EBITDA growth, driven by strategic transformation, acquisitions, and improved capital efficiency. Guidance for FY 2026 targets 15%+ organic revenue growth and margin expansion, with a continued focus on disciplined capital allocation.
Jagsonpal Pharmaceuticals shares drop 2.6% after USFDA issues warning letter for manufacturing lapses at API plant
Jagsonpal Pharmaceuticals shares fell over 2% after the US Food and Drug Administration (USFDA) issued a warning letter citing significant manufacturing lapses at its Rajasthan-based active pharmaceut...
Jagsonpal Pharmaceuticals acquires Resilient Cosmeceuticals’ India business for Rs 24 crore
Jagsonpal Pharmaceuticals Limited (BSE: 507789, NSE: JAGSNPHARM) has announced the acquisition of Resilient Cosmeceuticals Private Limited’s India business for ₹24 crore. The deal, funded through inte...
Jagsonpal Pharmaceuticals shares jump nearly 6% on strong Q3 FY25 results
Jagsonpal Pharmaceuticals Limited shares surged nearly 6% on January 23, 2025, following the announcement of its robust Q3 FY25 financial performance. The stock traded at ₹241, up by ₹12.75, reflectin...
Jagsonpal Pharmaceuticals Transcript: Q2 24/25
Q2 FY25 saw 29% revenue growth to INR 74.7 crores and a 53% rise in net profit, driven by recovery in core brands and the Yash Pharma acquisition. EBITDA margin guidance was raised to 22%+ for FY25, with continued focus on organic growth, operational efficiency, and selective inorganic expansion.
Jagsonpal Pharmaceuticals block trade: 22 lakh shares exchanged in ₹88 crore deal
On September 6, 2024, JAGSNPHARM witnessed a significant block trade during Session 1, with 22,00,000 shares exchanging hands at a steady price of ₹400.00. Despite the large transaction, the stock clo...